Litcius/Paper detail

Subacute cutaneous lupus erythematosus with positive anti‐Ro antibodies following palbociclib and letrozole treatment: A case report and literature review

Eleanor Russell‐Goldman, Rosalynn M. Nazarian

2020Journal of Cutaneous Pathology18 citationsDOI

Abstract

Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) is an uncommon but well-described phenomenon, most often seen in association with antihypertensives and antifungal medications. In recent years, rare reports of DI-SCLE have been described in patients being treated with targeted therapies. Herein, we describe a case of DI-SCLE in association with palbociclib and letrozole treatment for metastatic breast cancer. This report is the first known case of DI-SCLE with positive anti-Ro antibodies in this setting. We also summarize the literature describing DI-SCLE in association with targeted therapies to date and its possible association with dysregulation of the vascular endothelial growth factor pathway.

Topics & Concepts

MedicinePalbociclibSubacute cutaneous lupus erythematosusLetrozoleDermatologyBreast cancerCancerPathologyAntibodyMetastatic breast cancerImmunologyInternal medicineConnective tissue diseaseAromataseAutoimmune diseaseChronic Lymphocytic Leukemia ResearchAdvanced Breast Cancer TherapiesHER2/EGFR in Cancer Research
Subacute cutaneous lupus erythematosus with positive anti‐Ro antibodies following palbociclib and letrozole treatment: A case report and literature review | Litcius